Loading...
XKRX
084650
Market cap20mUSD
Jul 10, Last price  
756.00KRW
1D
-7.69%
1Q
-40.38%
Jan 2017
-78.19%
IPO
-69.86%
Name

Labgenomics Co Ltd

Chart & Performance

D1W1MN
XKRX:084650 chart
P/E
P/S
0.32
EPS
Div Yield, %
Shrs. gr., 5y
2.42%
Rev. gr., 5y
-5.90%
Revenues
88.16b
+2.63%
33,175,358,670119,478,054,000202,407,364,000144,772,746,00071,076,268,00085,898,311,00088,161,338,000
Net income
-64.37b
L+170.53%
962,421,37042,766,442,00083,854,994,00048,397,233,000-4,673,918,000-23,795,979,000-64,374,533,000
CFO
-30.54b
L+134.99%
3,188,085,83046,371,796,05065,361,946,00068,954,535,000-3,826,989,000-12,994,546,000-30,536,264,042
Dividend
Dec 28, 2022200 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

LabGenomics Co., Ltd. is a specialist in genetic molecular diagnostics, providing a diverse array of related products and services. The company's offerings encompass advanced technologies such as Next Generation Sequencing (NGS) and general Molecular Diagnostics. This enterprise was established on March 29, 2002, and its principal offices are located in Seongnam-si, South Korea.
IPO date
Jul 01, 2013
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT